Advertisement

Advertisement

SABS Stock Latest News

SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

The FlySAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

SABS Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

SABS Upcoming Earnings Report: What to Expect?

22d ago

SAB Biotherapeutics Launches Major Equity Financing Offering

PremiumCompany Announcements

SAB Biotherapeutics Launches Major Equity Financing Offering

27d ago

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

PremiumThe Fly

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

28d ago

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

PremiumThe Fly

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

29d ago

SAB Biotherapeutics announces common stock offering, no amount given

PremiumThe FlySAB Biotherapeutics announces common stock offering, no amount given

29d ago

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

The Fly

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

1M ago

SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data

Company Announcements

SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data

1M ago

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

PremiumThe Fly

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

1M ago

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

PremiumStock Analysis & Ideas

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

3M ago

SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook

PremiumCompany Announcements

SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook

3M ago

SAB Biotherapeutics Appoints New Independent Board Chair, Directors

PremiumCompany Announcements

SAB Biotherapeutics Appoints New Independent Board Chair, Directors

3M ago

SAB Biotherapeutics initiated with a Buy at UBS

PremiumThe FlySAB Biotherapeutics initiated with a Buy at UBS

3M ago

Aligos Therapeutics initiated with a Buy at UBS

The Fly

Aligos Therapeutics initiated with a Buy at UBS

3M ago

SAB Biotherapeutics appoints David Zaccardelli as board chair

The Fly

SAB Biotherapeutics appoints David Zaccardelli as board chair

3M ago

SAB Biotherapeutics files $300M mixed securities shelf

PremiumThe Fly

SAB Biotherapeutics files $300M mixed securities shelf

4M ago

SAB Biotherapeutics Launches New $75 Million ATM Program

PremiumCompany Announcements

SAB Biotherapeutics Launches New $75 Million ATM Program

4M ago

PremiumRatings

SAB Biotherapeutics: Favorable SAB-142 Safety Profile and De-Risked Phase 2b Design Underpin Buy Rating

4M ago

SAB Biotherapeutics initiated with a Buy at Guggenheim

PremiumThe Fly

SAB Biotherapeutics initiated with a Buy at Guggenheim

4M ago

SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

PremiumThe FlySAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

4M ago

SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

The Fly

SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

4M ago

Eleven new option listings and two option delistings on December 8th

The Fly

Eleven new option listings and two option delistings on December 8th

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >